Creating a vaccine to prevent lymphoma in HIV-infected individuals
Rational Vaccine Design to prevent HIV-Associated Lymphoma
This study is working on a new vaccine to help prevent certain types of lymphomas in people with HIV, especially those caused by the Epstein-Barr virus, by boosting the body's ability to fight the virus with special antibodies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11017842 on NIH RePORTER |
What this research studies
This research focuses on developing a vaccine aimed at preventing lymphomas associated with HIV infection, particularly those driven by the Epstein-Barr virus (EBV). It investigates the role of neutralizing antibodies in providing protection against EBV and aims to elicit high levels of these antibodies through innovative vaccine designs. The approach includes testing various vaccine candidates in animal models to assess their immunogenicity and protective efficacy. If successful, this vaccine could significantly reduce the risk of lymphoma in HIV-infected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are HIV-positive and at increased risk for developing EBV-associated lymphomas.
Not a fit: Patients who are HIV-negative or those who do not have a risk of developing lymphomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly lowers the risk of developing lymphomas in individuals living with HIV.
How similar studies have performed: Previous research has shown promise in using antibody-based approaches for viral infections, indicating potential for success in this novel vaccine strategy.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Mcguire, Andrew — Fred Hutchinson Cancer Center
- Study coordinator: Mcguire, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.